Mar 5, 2014
iCo Therapeutics Announces Final Eight Month Patient Visit in Phase 2 iDEAL Study
Feb 25, 2014
iCo Therapeutics Announces DTC Approval
Jan 27, 2014
iCo Therapeutics Inc. Completes C$6.75 Million Equity Financing

View All News (+)

Enter Your Email to Sign Up for
iCo Therapeutics Updates

Welcome to iCo Therapeutics

iCo Therapeutics Inc. is a Vancouver-based reprofiling company focused on redosing or reformulating drugs with clinical history for new or expanded indications.   iCo has exclusive worldwide rights to three products: iCo-007, in Phase 2 for the treatment of Diabetic Macular Edema (DME), iCo-008 (Bertilimumab), a product with Phase 2 clinical history to be developed for sight-threatening diseases; and an oral Amphotericin B delivery system for life-threatening infectious diseases. Immune Pharmaceuticals licensed systemic rights to iCo-008 in June 2011.     iCo trades on the TSX Venture Exchange under the symbol “ICO”.

iCo Therapeutics trades on the TSX-Venture exchange under the symbol "ICO".

Copyright 2010 ICO Therapeutics | Disclaimer